Amgen reported strong Q4 and full-year 2013 results with significant revenue and earnings growth, reinforced by strategic acquisitions and robust pipeline advancements. Despite guidance aligning closely with consensus expectations and an increased dividend, some analysts noted potential headwinds in revenue growth which may temper short-term optimism. Overall, the positive financial performance and strategic initiatives are likely to support the stock in the near term.

[1]